Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 162Fulvestrant 156Trastuzumab 155pembrolizumab 145Letrozole 136Carboplatin 118Capecitabine 105pertuzumab 104Specimen Handling 102Cyclophosphamide 102Anastrozole 90palbociclib 86abemaciclib 82Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 74trastuzumab deruxtecan 70Radiotherapy 62Biopsy 59Surveys and Questionnaires 56Gemcitabine 53130-nm albumin-bound paclitaxel 53sacituzumab govitecan 51olaparib 51Blood Specimen Collection 50Standard of Care 49Taxes 48Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
romiplostim × Breast × 1 year × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡